Bladder cancer is a frequently recurring disease with a very poor prognosis once progressed to invasive stages, and tumour-associated blood vessels play a crucial role in this process. In order to identify novel biomarkers associated with progression, we isolated blood vascular endothelial cells ( 
Introduction
Bladder cancer ranks among the top five most commonly diagnosed cancers of males in North America [1] and occurs either as non-invasive (NIBC, pTa) or invasive bladder cancer (IBC, stages pT1-pT4, depending on the degree of invasiveness). NIBCs have a good prognosis, with 94% of patients surviving ≥ 5 years after tumour resection. However, 35% of them will experience cancer recurrence within the first year after surgery, requiring additional surgical interventions [2] . In contrast, the 5-year survival of patients with IBC is much lower: 68% for pT2 (muscle-invasive) and < 15% for pT3 and pT4 (invasion into perivesical tissue and to distant organs, respectively) [3] , despite aggressive treatment including surgery (partial or complete cystectomy), radio-, and chemotherapy [4] . The lack of suitable biomarkers that would allow us to reliably predict patients likely to suffer from cancer recurrence and/or progression remains a major obstacle for a more efficient treatment of bladder cancer.
We previously reported that the tumour-associated blood vasculature plays an important role in the progression of bladder cancer and identified endocan, a transcriptional target of VEGF-A, as a marker of tumour vessels and a mediator of angiogenesis [5] . However, targeted therapy to block VEGF-A (e.g. using bevacizumab) or its cognate receptors has shown no194 F Roudnicky et al unknown how the microenvironment in IBC contributes to tumour invasiveness and metastasis, but it is conceivable that the highly angiogenic vasculature is directly or indirectly involved in these processes. Therefore, we aimed to identify additional vascular proteins or pathways which could serve as prognostic markers and/or targets for future therapy. Transcriptional profiling of tumour-associated blood vascular endothelial cells (tBECs) from IBC compared with endothelial cells from adjacent normal bladder tissue (nBECs) revealed a strong up-regulation of insulin receptor (INSR). Importantly, we found that vascular INSR expression levels closely correlated with survival parameters, suggesting it as a new biomarker for disease progression. Concomitantly, the INSR ligand IGF-2 was up-regulated in the cancer tissue, suggesting that there is active crosstalk between cancer and endothelial cells via IGF-2/INSR signalling in IBC. In addition, we identified tissue hypoxia as the underlying mechanisms for the up-regulation of INSR and IGF-2, and investigated the functional role of this pathway in angiogenesis and tumour progression both in vitro and in a mouse model of bladder cancer.
Materials and methods

Tumour and normal tissue samples
Clinically annotated frozen and paraffin-embedded cancer and normal tissue samples were obtained from the University Hospital Zurich (USZ). Tissue collection was approved by the SPUK-GGU-USZ Ethics Committee (KEK-StV-Nr 02/09) and written informed consent was obtained from each patient.
Laser capture microdissection and transcriptional profiling of blood vessels from bladder tissue
Laser capture microdissection on frozen samples of IBC (five patients; pT1-pT4), RNA isolation, cDNA generation, and microarray hybridization were performed as previously described [5] . The microarray data have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO series accession number GSE41614 (https://www.ncbi.nlm.nih.gov/geo/query/ acc.cgi?acc=GSE41614).
Immunohistochemistry on human paraffin-embedded tissue samples
Immunohistochemical staining of paraffin-embedded tissue sections and the TMAs was performed as previously described [5] , using a mouse monoclonal anti-human INSR antibody (4 μg/ml, clone CT-3, AHR0271, Invitrogen, Carlsbad, CA, USA), using a rabbit polyclonal anti-human GLUT1 antibody (1:1000, AB1341; Merck Millipore, Billerica, MA, USA), as well as a biotin-labelled horse anti-mouse (5 μg/ml) antibody BA-2001 (Vector Labs, Burlingame, CA, USA). Signals were detected with avidin-coupled peroxidase and 3-amino-9-ethylcarbazole (AEC) or 3,3'-diaminobenzidine (DAB).
Endothelial cell migration assays
The monolayer wound healing assay was performed as previously described [8] . Details may be found in the supplementary material, Supplementary materials and methods.
Tumour mouse model
Tie2-Cre and INSR fl/fl mice on a C57Bl6 background have been described previously [9] [10] [11] The smallest and largest tumour diameters were measured with a digital caliper every second day, and tumour volumes were calculated as volume = π/6 × (smaller diameter 2 × larger diameter). On day 14 after tumour implantation, animals were injected i.p. with the hypoxia marker pimonidazole hydrochloride (NPI Inc, Burlington, MA, USA) (60 mg/kg, 1 h before sacrifice) and with luciferine (IRIS Biotech, Marktredwitz, Germany) (150 mg/kg, 10 min before sacrifice). Right after sacrifice, the primary tumour, inguinal and axillary lymph nodes, lungs, and livers were dissected and imaged using an IVIS system (Caliper Life Sciences, Hopkinton, MA, USA). All experiments were performed in accordance with animal protocol 12/2015 approved by the Kantonales Veterinaeramt Zurich.
Results
High expression levels of insulin receptor on blood vessels of bladder cancers are associated with shorter progression-free and overall survival of patients
We previously performed a transcriptional analysis of bladder cancer-associated blood endothelial cells (tBECs) compared with adjacent normal bladder endothelial cells (nBECs) using laser capture microdissection (LCM) and microarray analysis [5] . The high purity of captured endothelial cell content was conINSR up-regulation on blood vessels in bladder cancer 195 We noticed a highly significant up-regulation (>4-fold up-regulation, p adj < 0.01) of insulin receptor (INSR) in tBECs and decided to investigate this phenomenon further, due to the potential effects of this important receptor on cell metabolism and angiogenesis. RT-qPCR analysis confirmed that INSR mRNA expression was highly increased in five samples of tBECs compared with nBECs ( Figure 1A) , and the presence of INSR protein expression on tumour-associated vessels of a BC specimen was validated by immunostaining ( Figure 1B) . Of note, immunohistochemical analysis revealed that INSR is up-regulated in the vasculature of various other solid tumour types (supplementary material, Figure  S1 ). INSR expression was, however, undetectable on blood vessels in various healthy tissues, indicating that INSR is a general tumour vessel marker (supplementary material, Figure S2 ). Semi-quantitative measurement of vascular INSR expression in 63 samples of IBC ( Figure 1C and supplementary material, Table S1 ) followed by Kaplan-Meier analysis revealed that the progression-free survival and overall survival of patients with strong vascular INSR expression (n = 12, N events =8 and n = 12, N events =9, respectively) were much shorter than those of patients with no or weak expression (n = 51, N events =19, p = 0.003, Figure 1D ; n = 51, N events =23, p = 0.004, Figure 1E ). We also analysed INSR expression in 90 NIBC cases [13] ( Figure 1F , and supplementary material, Table S2 ). The patients with strong vascular INSR expression (n = 53, N events =31) had a tendency for shorter recurrence-free survival times than those with no or weak expression (n = 37, N events =16, p = 0.087; Figure 1G ). In contrast, INSR staining in tumour cells was absent or very weak in all the tumour samples that we analysed, indicating that tBECs are the strongest INSR-expressing cells within the BC microenvironment ( Figure 1C, F) . Using a publicly available TCGA dataset on invasive cancer [14] , we observed that INSR was significantly up-regulated in papillary-like luminal cluster I (N (cluster I) = 43; N (cluster II) = 50, p < 0.01; N (cluster III) = 35, p < 0.001; N (cluster IV) = 15, p < 0.001; supplementary material, Figure S3A ). Interestingly, the same cluster showed significant up-regulation of endocan, a molecule that we have previously identified to correlate with invasiveness of BC and angiogenesis [5] . Moreover, the same cluster showed significant down-regulation of thromspondin-1 (TSP1). We have previously found that TSP1 is anti-angiogenic and has tumour-suppressing activity [15, 16] . Besides, IBC patients with low TSP1 expression showed decreased overall survival and increased microvascular density [17] . Based on these findings, it is possible that the papillary-like luminal cluster I is particularly dependent on angiogenesis and could benefit from anti-angiogenic therapy.
We also compared the expression of INSR in IBCs of different histology from the TCGA database [14] and identified significantly higher expression (p < 0. 
INSR expression by blood vascular endothelial cells is up-regulated upon hypoxia
Due to their high rate of proliferation and chaotic blood vessel network, the majority of cancers are hypoxic [18, 19] . As we saw high expression of INSR on tBECs in the majority of solid cancers, we therefore hypothesized that hypoxia might be responsible for endothelial INSR expression. Human umbilical vein endothelial cells (HUVECs) and human dermal blood vascular endothelial cells (BECs) were exposed to hypoxia for 24 h, and the expression of INSR was analysed by RT-qPCR. Hypoxia led to increased INSR expression ( Figure 2A ; 1.7-to 3.1-fold and 1.4-to 3.8-fold, respectively). On the other hand, among the four BC cell lines tested, only the one derived from high-grade cancer (T24; grade III) up-regulated INSR expression upon hypoxia (1.4-to 2.2-fold; Figure 2B ). This indicates that INSR expression is regulated by hypoxia specifically in endothelial cells.
In order to test whether hypoxia might also be responsible for vascular INSR expression in human BC, we indirectly assessed the level of hypoxia in 63 IBC cases (same as in Figure 1C and supplementary material, Table S1 ) by staining for the hypoxia-responsive marker GLUT1 (SLC2A1; Figure 2C [20, 21] ). Semi-quantitative scoring of GLUT1 expression revealed a clear trend for association between INSR and GLUT1 staining (GLUT1 low/INSR low = 27, GLUT1 high/INSR low = 24, GLUT1 low/INSR high = 3, GLUT1 high/INSR high = 9, p = 0.08; Figure 2D ). Of note, significantly increased expression of GLUT1 was also detected in LCM-isolated blood vascular endothelial cells from five BCs (tBECs) compared with that from the adjacent normal bladder tissue (nBECs), suggesting that the tBECs themselves were also hypoxic to some extent (516.5-to 6897.0-fold; Figure 2E ). Furthermore, GLUT1 expression and INSR expression were significantly correlated in these samples (p = 0.02, r = 0.72; Figure 2F ). In line with this, in addition to high intensity staining of GLUT1 in tumour cells, we could observe weak GLUT1 staining in vessels in the vicinity of tumour cells. Furthermore, GLUT1 up-regulation was also detectable in BECs exposed to hypoxia in vitro (4.4-to 6.0-fold; supplementary material, Figure S4A ).
GLUT1 has been shown to be induced by hypoxia-inducible factor 1A (HIF1A) [22] , a transcription factor that becomes transcriptionally active upon a decrease in tissue oxygen levels and that induces the expression of several hypoxia response genes [23] . We therefore hypothesized that INSR is also under Figure 2F ). Interestingly, the H3K27ac mark in this putative enhancer region was only observed under hypoxia. Typically, enhancer elements interact with the TSS of a gene to up-regulate its expression. To investigate this link, we utilized ChIA-PET data [24] , which map regions that are in close chromosomal proximity, and observed a clear interaction between the putative enhancer and the TSS of INSR ( Figure 2F ). Taken together, these findings suggest that the enhancer and its interaction with HIF1A and the TSS of INSR are important for the up-regulation of INSR transcription.
Insulin receptor isoform-A is the major isoform expressed in tumour-associated endothelial cells and in endothelial cells in vitro
Two alternative splice isoforms of INSR have been described. The INSR-A isoform lacks exon 11, which encodes 12 amino acid residues at the C-terminus. INSR-A binds to IGF-2 with very high affinity, in contrast to INSR-B [25] , which is expressed predominantly in insulin-responsive tissues (liver, muscle, adipose tissue, and kidney).
In LCM-isolated tBECs, the majority of the INSR transcript consisted of INSR-A ( Figure 3A) , while in LCM-isolated endothelial cells from healthy bladder tissue, expression of both isoforms was very low (at the limit of detection for RT-qPCR; data not shown). Similarly, in vitro cultured BECs and HUVECs showed higher expression of INSR-A compared with INSR-B (14.5-to 31.7-fold, BECs; 6.1-to 24.8-fold, HUVECs).
IGF-2 is up-regulated by hypoxia and higher levels of IGF-2 are associated with shorter overall survival of patients with IBC
We then investigated if hypoxia might also induce the expression of two physiological ligands of INSR, IGF-1 and IGF-2. When subjected to hypoxia, BECs expressed increased levels of IGF-2 (1.4-to 1.9-fold; Figure 4A) but not of IGF-1 (0.9-to 1.1-fold; supplementary material, Figure S4B ). Cultured BC and urothelial cells reacted with an even more pronounced increase in IGF-2 expression ( Figure 4B ), while IGF-1 expression was undetectable (data not shown). To test whether hypoxia observed in human BC was associated with increased IGF-2 expression as well, we analysed several publicly available gene expression datasets of total BC and control bladder tissue [26] [27] [28] . Analysis of these three datasets revealed significantly higher IGF-2 expression levels in IBC compared with normal bladder tissue (NB) and with normal bladder tissue that was adjacent to BC (NAB) (from ref 26: 2.6-fold higher in IBC (n = 85) than in NAB (n = 45), Figure 4C ; from ref 27: 6.8-and 5.8-fold higher in IBC (n = 13) than in NB (n = 9) and NAB (n = 5), respectively, Figure 4D ; from ref 28: 2.8-and 2.5-fold higher in IBC (n = 141) than in NB (n = 10) and NAB (n = 58), respectively, Figure 4E) . Two of the datasets also included expression from NIBC, in which IGF-2 expression was also elevated (from ref 27: 8.0-and 6.9-fold higher expression in NIBC (n = 15) than in NB (n = 9) and NAB (n = 5), respectively, Figure 4C ; and from ref 28: 1.8-and 1.6-fold higher expression in NIBC (n = 24) than in NB (n = 10) and NAB (n = 58), respectively, Figure 4D) .
The large number of IBC samples and long clinical follow-up in one of the datasets [28] allowed us to compare the overall survival of patients with higher versus lower IGF-2 expression. Based on receiver operating characteristic (ROC) analysis, patients were stratified into two groups of high [log 2 expression > 9.86 (n = 73, N events = 21)] and low IGF-2 expression [log 2 expression < 9.86 (n = 68, N events = 10)]. Kaplan-Meier analysis revealed that the survival times of patients with high expression of IGF-2 tended to be shorter (p = 0.096, Figure 4F ). In addition, when we analysed the dataset from the Cancer Genome Atlas project (TCGA) for BC [14] , again dividing patients into a high and a low IGF-2 expression group by ROC analysis [log 2 expression > or < 6.9 (n = 86, N events =31 and n = 91, N events = 24, respectively)], high IGF-2 expression was significantly associated with a shorter survival Figure 4G ). Taken together, these data suggest that hypoxia initiates crosstalk between IGF-2-expressing BC cells and INSR-expressing endothelial cells, which strongly correlates with a poor prognosis.
IGF-2 activates endothelial migration though INSR independently of VEGFR-2
Next, we sought to determine whether INSR stimulation is involved in cellular processes that contribute to angiogenesis. Using the endothelial scratch closure assay, we tested the effect of known agonists of INSR (insulin, IGF-1, IGF-2) on endothelial migration. The strongest inducer of EC migration was IGF-2 (500 ng/ml, a concentration within the physiological range of 200-800 ng/ml [29] ; 19.5-27.9% scratch closure above control; Figure 5A ), followed by insulin (1 μM, 16.6-16.9%, supplementary material; Figure  S5A ) and IGF-1 (500 ng/ml, 12.6-19.2%; supplementary material, Figure S5B ). IGF-2 used at 100 ng/ml induced cell migration almost efficiently as VEGF-A (20 ng/ml), the most powerful inducer of EC migration (11.0-23.1% relative scratch closure above control, Figure 5B ). The strong effect of IGF-2 compared with insulin or IGF-1 is in accordance with the predominant expression of INSR-A by cultured BECs and HUVECs noted earlier, which binds IGF-2 with high affinity. One of the ways that resistance to VEGF-A angiogenesis inhibitors arises is due to up-regulation of other pro-angiogenesis factors [30, 31] . Interestingly, we found that the migration-stimulatory effect of IGF-2 on cultured endothelial cells was independent of VEGFR-2 ( Figure 5B ). To confirm that the prominent activity of IGF-2 on endothelial cells was indeed mediated by INSR, we used an INSR-specific blocking antibody (IR Ab) [32] , an inhibitor of IGF-1R activation, picropodophyllin (PPP), and an inhibitor of both INSR and IGF-1R activation, GSK1838705. IR Ab used at 10 nM completely blocked the IGF-2-induced migration ( Figure 5C ); PPP (50 nM) only partially inhibited the IGF-2-induced migration ( Figure 5D) ; and GSK1838705 (100 nM) completely blocked the migration induced by IGF-2 ( Figure 5E ). Furthermore, we found that IR Ab (10 nM) blocked the effect of insulin (supplementary material, Figure S5C ) but not that of IGF-1 (supplementary material, Figure S5D ), while PPP (50 nM) successfully blocked IGF-1 action (supplementary material, Figure S5E ). GSK1838705 (100 nM) successfully blocked the action of insulin and IGF-1 (supplementary material, Figure S5F , G) as expected. Thus, BEC migration induced by insulin and IGF-2 appears to involve INSR, whereas the effect of IGF-1 is only mediated by IGF-1R. On the other hand, the proliferation of BECs and HUVECs under normoxic and hypoxic conditions was hardly affected by treatment with insulin, IGF-1 or IGF-2 (supplementary material, Figure S6 ), whereas VEGF-A (used as a positive control) induced BEC and HUVEC proliferation 1.5-to 2.0-fold. Figure 6A ). In these mice, Tie2-promoter-driven Cre expression led to efficient deletion of INSR ( Figure 6B ). Fourteen days after tumour inoculation, the tumour sizes and tumour weights in the two groups were similar (Figure 6C, D) . (HTB2 and HTB9) , and differentiated urothelium (UROtsa), after 24 h of hypoxia (1% O 2 ). (C-E) IGF-2 expression in both invasive and non-invasive bladder cancers (IBC and NIBC) was compared with IGF-2 expression in normal bladder tissue (NB) and/or normal tissue adjacent to bladder cancers (NAB) using the publicly available datasets from Sanchez-Carbayo et al [26] (C), Dyrskjot et al [27] (D), and Lee at al [28] (E). (F, G) Kaplan-Meier curves of patient survival were compared between the IBCs expressing higher IGF-2 levels and those expressing lower levels in the study by Lee et al (F) and between the bladder cancers expressing higher and lower IGF-2 levels from the TCGA (G). Data are presented as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001. Horizontal lines in C-E denote mean values.
Deletion of insulin receptor expression in blood vascular endothelial cells in vivo does not affect angiogenesis but attenuates tumour metastasis
However, we observed a tendency towards a reduced incidence of lymph node metastasis in endothelial INSR-deficient (Cre+) mice ( Figure 6E ). No difference in the incidence in either liver or lung metastasis was detectable ( Figure 6F ), but we noted a tendency for a reduced size of metastases at these sites in Cre + mice, based on bioluminescence measurements ( Figure 6G) . Furthermore, histological analysis of the primary tumours revealed no obvious differences in the blood vessel density ( Figure 6H) or area, or in the hypoxic (pimonidazole-positive) area ( Figure 6H-J) , indicating that tumour angiogenesis is not dependent on INSR signalling in endothelial cells, but that endothelial INSR may be involved in the metastatic process.
Discussion
IBC is a dreadful disease, which, despite aggressive therapy such as complete cystectomy, has a high tendency to recur and generally a very poor prognosis.
Our study reveals that high vascular INSR expression correlates with much lower progression-free and overall survival in IBC. INSR may therefore represent a novel prognostic biomarker for this disease. Although associated with a much better prognosis than IBC, NIBCs also have a high risk to recur, and there are no biomarkers to predict recurrence [33] . Currently, patients have to undergo cystoscopies repeatedly [34] , which are time-consuming, expensive, and can cause damage to the urethra or lead to urinary tract infection [35] . Also in this case, high INSR expression on the vasculature of NIBC was associated with a tendency for more rapid recurrence of the tumour. Therefore, assessing INSR expression in tumour biopsies could contribute to a more accurate prediction of recurrence in NIBC. Due to the limited sample size of our cohort, we were not able to reliably calculate whether vascular INSR was an independent predictor in a multivariate analysis. Therefore, additional studies using larger patient cohorts are warranted. Interestingly, in published expression datasets for IBC (TCGA [14] ), we found increased expression of INSR in the papillary-like luminal cluster I compared with other identified clusters. This cluster also showed up-regulation of endocan and down-regulation of thrombospondin 1, suggesting that this cluster could be angiogenic. Furthermore, increased expression of INSR was found in IBC of papillary histology versus IBC of non-papillary histology.
Regarding the mechanism behind INSR up-regulation, our data suggest that INSR is directly triggered by hypoxia, which was frequently present in BC tissue, via activation of HIF1A. INSR expression correlated with the expression of GLUT1, a hypoxia-responsive gene, in BC tissue, and GLUT1 expression in isolated tBECs suggested that the tumour-associated endothelium might be hypoxic itself. We also identified a putative enhancer of INSR which interacts with HIF1A and which may be responsible for the hypoxia-inducible INSR up-regulation in BECs. Interestingly, we could not detect up-regulation of INSR in BC cells by immunohistochemical staining in spite of the presence of hypoxic (GLUT1-positive) regions in BC tissue, indicating that HIF1A induces INSR transcription only in ECs, possibly due to inactivation of the responsible enhancer region in BC cells.
On the other hand, hypoxia led to increased production of IGF-2 by cultured BECs and BC cells. Re-analysis of several large transcriptional profiling studies showed that IGF-2 is up-regulated in human BCs compared with normal bladder tissue and that high IGF-2 expression levels were associated with reduced overall survival of patients with IBC, even though the difference was not as pronounced as that for high INSR expression. The finding of elevated IGF-2 production by the tumours and preferential up-regulation of INSR-A expression on the tBECs strongly suggests activation of paracrine crosstalk between tumour cells and tBECs, which correlates with poor prognosis.
It is interesting to note that several epidemiological studies have revealed that patients with diabetes mellitus type 2 have an increased incidence and mortality of BC [36] and a higher incidence of IBC [37] . In patients with non-muscle IBC (pTa, pT1), diabetes mellitus type 2 was reported to be an independent risk factor for recurrence and to correlate with more aggressive features of the cancer [38, 39] . It can be speculated that in diabetes mellitus type 2, INSR expression levels on blood vessels are elevated to compensate for reduced insulin signalling, and that this leads to the worsened prognosis for BC in diabetes mellitus type 2 patients by the mechanisms shown in the present study. Interestingly, in our study, only in the samples with INSR-positive staining could we also find patients with diabetes mellitus.
Despite the prognostic value of INSR and IGF-2 expression in BC, it is not entirely clear what the functional consequence of this signalling pathway is, and whether it could serve as a therapeutic target as well. Our in vitro data suggest that IGF-2 binding to endothelial cell-expressed INSR stimulates endothelial migration, indicating a pro-angiogenic activity. On the other hand, we found no effect of IGF-2 on endothelial proliferation in vitro, and the blood vessel density in tumours of mice lacking INSR expression in endothelial cells was not altered. Therefore, IGF-2/INSR signalling may promote angiogenesis but is clearly not required in vivo, at least as long as other angiogenic pathways in the tumour microenvironment remain intact. It is tempting to speculate that the role of the IGF-2/INSR pathway in tumour angiogenesis is redundant with other pathways, such as the VEGF-A/VEGFR-2 pathway, and may compensate in the case of VEGF-A targeted therapy, which may explain the resistance of BC to this therapy. Indeed, our in vitro data show that IGF-2 can stimulate endothelial migration even in the presence of VEGFR-2 blocking antibodies.
On the other hand, our findings that INSR deletion in endothelial cells slightly reduced tumour metastasis in tumour draining and non-draining lymph nodes, as well as in the lung and liver, opens the possibility that INSR signalling may control other endothelial parameters, e.g. endothelial permeability, which may facilitate the systemic spread of cancer cells via the blood circulation. IBC [14] -cancers with lymphovascular invasion and IBCs that metastasized had significantly increased levels of INSR.
From a pharmacological point of view, specific targeting of INSR-A, in contrast to INSR-B, which is involved in the metabolic effects of insulin in muscle, adipose tissue, and liver [40] , could well become a novel and safe strategy in BC treatment as it avoids metabolic adverse effects. Another approach could be to target IGF-2. A dual IGF-1/-2 neutralizing antibody was indeed successful in preclinical tumour mouse studies [41] . Currently, this antibody is in clinical trials for metastatic breast cancer [42] . Based on our results presented here, IBC may represent another indication for this drug in the future. 
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